Survodutide
Availability Clinical trials only
What it is
Survodutide is an investigational dual agonist of the GLP-1 and glucagon receptors, developed by Boehringer Ingelheim with Zealand Pharma. Like retatrutide it recruits glucagon signaling to raise energy expenditure rather than working on appetite alone. Unlike most of the class, it has been aimed as much at the liver as at the scale.
Why people take it
Because it is next in line, and because of the liver data. People following the pipeline see a drug that clears liver fat as well as body weight, which speaks to a metabolic problem that weight loss alone addresses less directly. Vials labeled survodutide have begun appearing in the same unregulated vendor channel that already carries retatrutide, on the same logic of not waiting.
How it's delivered
A weekly subcutaneous injection in the trial protocols, titrated over several months under supervision. There is no approved product, no approved dose, and no legitimate route to it outside a study.
Where the evidence stands
Good Phase 3 data, no approval anywhere. SYNCHRONIZE-1, reported in April 2026, showed average weight loss of up to 16.6 percent at 76 weeks against 3.2 percent on placebo. SYNCHRONIZE-MASLD, reported in June 2026, met both primary endpoints, with liver fat normalizing in roughly six of ten participants at 48 weeks. Earlier Phase 2 work in MASH showed improvement in fibrosis without worsening of disease. Tolerability is the visible cost: close to one in five participants stopped for gastrointestinal side effects, against about 3 percent on placebo. There are no outcome, mortality, or aging data.
Estimated cost
- No approved product and no legitimate price
- Free to participants inside a clinical trial
- No insurance pathway exists
Who offers it
No one offers survodutide legitimately. The only lawful route is enrollment in the Phase 3 program, listed on the public registry. Material sold online as survodutide sits outside the approval system, and neither its identity nor its concentration has been established by anyone the buyer can hold to account.
Recorded from the trial registry and sponsor announcements on our last research pass. We list no referral path to this treatment and are not compensated for this entry.
Go deeper
No survodutide guide yet. Our GLP-1 guide covers the approved drugs in the same family, which is the standard any new incretin drug has to clear.
Longevity.io is for educational purposes only and is not medical advice. We cover survodutide because it is already being sold, not because an unapproved vial from an unregulated vendor is a reasonable option. If the drug interests you, the trial registry is the place to look.
Build your starting plan.
A few short questions, about two minutes. The Blueprint recommends where to start and explains why.
Build my Blueprint
